The number of shares and votes in CELLINK AB (publ) have increased as a result of a directed new issue of 284,176 shares of series B which was carried out as a part of the financing for the acquisition of MatTek Corporation. The Board of Directors resolved on an issue in kind on March 22, 2021 in accordance with the authorization from the Extraordinary General Meeting held on December 17, 2020.

Through the above mentioned event, which the Swedish Companies Registration Office registered during April, the number of shares and votes in CELLINK increased by a total of 284,176.

As of April 30, 2021, the total number of registered and outstanding shares of CELLINK amounts to 56,577,398, of which 1,500,000 are shares of series A and 55,077,398 are shares of series B, corresponding to a total of 70,077,398 votes. The share capital amounts to SEK 1,414,434.950. The company does not hold any treasury shares.

For further information, please contact:

Gusten Danielsson, CFO                            
Phone (US): +1 (857) 332 2138

Phone (Sweden): +46 709 91 86 04     
Isabelle Ljunggren, Head of Communications                            
Phone: +46 708 30 08 90


This is information that CELLINK AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on April 30, 2021, at 08:00 a.m. (CEST).


Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,600 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq the Stockholm under CLNK B.